Haier Biomedical reports mixed first half, net profit falls despite overseas growth

Qingdao Haier Biomedical Co., Ltd. announced a decrease in operating income by 2.27% to 1,195,500,051.78 yuan and a significant drop in net profit attributable to shareholders by 39.09% to 142,739,180.80 yuan for the first half of 2025. This performance is attributed to complex global and industry conditions, alongside high comparative base figures and strategic investments. Despite domestic market pressures, overseas revenue saw a 30.17% increase to 427 million yuan.

The company continues to prioritize technological innovation, investing 160.11 million yuan in R&D, a 13.39% share of operating income. Advancements were made in AI-driven solutions across low-temperature storage, laboratory, smart pharmacy, and blood technology sectors. Haier Biomedical maintained a robust global presence, with products and solutions deployed in over 150 countries and regions.

In investor returns, the company completed a share repurchase of 1,636,800 shares, totaling approximately 50 million yuan. A cash dividend of 4.7 yuan per 10 shares was distributed, representing 40.18% of the net profit attributable to listed company shareholders for 2024. Furthermore, Haier Biomedical granted 500,000 restricted shares to 59 key employees at 14.90 yuan per share.